MDS subclassification—do we still have to count blasts?
Open Access
- 22 February 2023
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 37 (4) , 942-945
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDSLeukemia, 2022
- Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic SyndromesJournal of Clinical Oncology, 2021
- The Genetics of Myelodysplastic Syndromes: Clinical RelevanceGenes, 2021
- Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic SyndromesJournal of Clinical Oncology, 2021
- Co-occurrence of RUNX1 and ASXL1 mutations underlie poor response and outcome for MDS patients treated with HMAs2019
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- The genetic basis of myelodysplasia and its clinical relevanceBlood, 2013
- Clinical and biological implications of driver mutations in myelodysplastic syndromesBlood, 2013
- Landscape of genetic lesions in 944 patients with myelodysplastic syndromesLeukemia, 2013
- Prognostic Significance ofASXL1Mutations in Patients With Myelodysplastic SyndromesJournal of Clinical Oncology, 2011